查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403512

到 2030 年肌瘤摘除的市場預測：按產品類型、最終用戶和地區進行的全球分析

Myomectomy Market Forecasts to 2030 - Global Analysis By Product, Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球肌瘤摘除市場規模為 7.5659 億美元，預計到 2030 年將達到 15.8073 億美元，預測期內複合年成長率為 11.1%。

肌瘤摘除是一種外科手術，旨在從子宮肌肉壁上移除稱為子宮肌瘤的非癌性生長物。對於想要避免子宮切除術或想要保留生育能力的女性來說，這是一個可行的選擇。此外，這種手術可以使用多種技術進行，包括開放性手術、腹腔鏡手術和機器人輔助手術。

根據婦女健康研究協會的報告，美國約有2600萬15歲至50歲的女性患有子宮肌瘤。

子宮肌瘤盛行率增加

子宮肌瘤是常見的良性腫瘤，影響大量女性，尤其是在生育期。例如，根據伊利諾伊州公共衛生部的數據，大約 77% 的生產婦女可能患有子宮肌瘤。因此，隨著越來越多的女性被診斷出患有子宮肌瘤，越來越需要有效的治療解決方案來控制由此產生的症狀。此外，腹腔鏡和機器人輔助手術等微創技術在子宮肌瘤切除術中也越來越受歡迎。子宮肌瘤盛行率的增加刺激了對子宮肌瘤摘除的需求並推動市場擴張。

生育問題

儘管肌瘤摘除的目的是透過切除子宮肌瘤來保護生育能力，但它也會影響生育能力。手術，尤其是子宮肌瘤是多個或較大的，可能會導致子宮疤痕或變化，進而影響生育能力。肌瘤摘除對生育問題的擔憂影響了未來想要孩子的女性。這可能會影響治療決策流程，甚至限制市場擴張。

微創手術需求不斷成長

越來越多的患者喜歡腹腔鏡或機器人輔助肌瘤摘除切除術等微創手術，以獲得更快的恢復時間、更少的疤痕並更快地恢復日常活動。這種日益成長的偏好與對有效且微創治療方法的渴望不謀而合，特別是在尋求保留生育能力的女性身上。此外，提供這些先進手術的醫療保健提供者將能夠吸引更多尋求肌瘤摘除的患者，滿足對微創選擇不斷成長的需求並擴大他們的市場。

手術以外的選擇

子宮動脈栓塞（UAE）和聚焦超音波手術（FUS）等先進的非手術治療為無需手術的子宮肌瘤治療提供了有效的選擇。這些非手術治療的可用性和成功率不斷提高，對傳統肌瘤摘除市場構成了挑戰，有可能減少對外科手術的需求，並增加無需手術干預的子宮肌瘤切除術的可用性。

COVID-19 的影響

COVID-19 疫情嚴重影響了女性醫療保健和子宮肌瘤摘除市場。 COVID-19 的爆發導致診斷和治療的延誤以及醫療機構中非緊急治療的延遲。此外，供應鏈中斷導致難以取得子宮肌瘤摘除所需的醫療用品。此外，醫院挪用了用於 COVID-19 治療的資金，影響了他們對非緊急醫療活動的關注。因此，COVID-19 限制了子宮肌瘤摘除市場的成長。

在預測期內，腹腔鏡子宮肌瘤摘除部門預計將是最大的。

腹腔鏡子宮肌瘤摘除預計佔最大佔有率。腹腔鏡肌瘤摘除是一種微創手術，用於切除子宮肌瘤。此手術使用一個小切口，透過該切口插入特殊器械和腹腔鏡，以提供子宮的放大視圖。其他好處包括更短的住院時間、更快的康復和更少的術後併發症。越來越多的患者對微創選擇的偏好以及腹腔鏡技術的進步繼續使該領域成為子宮肌瘤的治療方法。

醫院和診所領域預計在預測期內複合年成長率最高

預計醫院和診所部門在預測期內將出現良好的成長。醫院和診所配備先進的醫療基礎設施和熟練的醫療專業人員，為尋求各種子宮肌瘤治療方法的患者提供服務。我們提供全面的診斷評估、手術專業知識和術後護理，以滿足患者對各種手術方法的需求，包括腹腔鏡手術、機器人輔助手術和開放式肌瘤摘除。此外，醫院和診所在提供專業護理方面發揮著至關重要的作用，透過肌瘤摘除為子宮肌瘤的可及性和綜合管理做出了重大貢獻。

比最大的地區

由於患有子宮疾病的女性人數不斷增加以及新興經濟體主要企業對手術器械行業的投資增加，亞太地區在估計期間佔據了最大的市場佔有率。中國和日本在擴大肌瘤摘除市場方面發揮重要作用。包括外科醫生和婦科醫生在內的高技能醫療人員的供應不斷增加，以及對用於研究目的的基因晶片等技術先進的醫療技術的需求不斷增加，是這一成長的主要原因。

複合年成長率最高的地區：

由於子宮肌瘤盛行率的上升和子宮肌瘤摘除的技術進步，預計北美在預測期內將出現有益的成長。根據美國婦女健康局2021年2月更新的資料，預計約20%至80%的女性會在50歲時罹患子宮肌瘤。 40多歲到50歲出頭的女性最容易罹患子宮肌瘤。儘管並非所有子宮肌瘤都會引起症狀，但患有子宮肌瘤的人通常會發現與子宮肌瘤一起生活很困難。如上所述，由於美國子宮肌瘤的高負擔，市場預計將成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球肌瘤摘除市場：依產品

  • 腹腔鏡動力粉碎器
  • 腹腔鏡封堵器
  • 和諧女性
  • 其他產品

第6章全球肌瘤摘除市場：依類型

  • 腹部子宮切除術
  • 腹腔鏡切除術
  • 子宮鏡切除術術
  • 機器人切除術

第7章全球肌瘤摘除市場：依最終用戶分類

  • 門診手術中心
  • 醫院/診所
  • 其他最終用戶

第8章全球肌瘤摘除市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Medtronic
  • Conmed Corporation
  • Stryker Corporation
  • Insightec
  • Hologic, Inc
  • Cooper Surgical Inc
  • Intuitive Surgical
  • Braun Melsungen AG
  • Minerva Surgical Inc
  • Johnson And Johnson Services Inc.
  • Karl Storz
  • Boston Scientific Corporation
  • General Electric Company
  • F. Hoffmann-La Roche Ltd
  • Richard Wolf Medical Instruments
  • Siemens
  • Bayer
  • AbbVie Inc.
  • Halt Medical, Inc.
Product Code: SMRC24737

According to Stratistics MRC, the Global Myomectomy Market is accounted for $756.59 million in 2023 and is expected to reach $1580.73 million by 2030 growing at a CAGR of 11.1% during the forecast period. A myomectomy is a surgical procedure aimed at removing noncancerous growths known as uterine fibroids from the muscular wall of the uterus. It is a viable alternative for women who want to avoid a hysterectomy or maintain their fertility. Furthermore, a number of techniques, such as open surgery, laparoscopy, and robotic-assisted surgery, can be used to carry out this procedure.

According to the Society for Women's Health Research report, in the U.S. approximately 26 million women ages 15-50 have uterine fibroids.

Market Dynamics:

Driver:

Growing prevalence of uterine fibroids

Uterine fibroids are common benign tumours affecting a substantial number of women, particularly during their reproductive years. For instance, according to the Illinois Department of Public Health, around 77% of women of childbearing age may have uterine fibroids. Therefore, as more women have uterine fibroids diagnoses, there is a growing need for efficient treatment solutions to manage the resulting symptoms. Furthermore, minimally invasive techniques such as laparoscopy and robotic-assisted surgery are gaining popularity in myomectomy. This growing prevalence of uterine fibroids fuels the demand for myomectomy procedures, propelling the market's expansion

Restraint:

Fertility concerns

Myomectomy has the potential to affect fertility ability, even if the aim is to protect fertility by removing uterine fibroids. The surgical procedure, especially if multiple or large fibroids are removed, might lead to scarring or alterations in the uterus, potentially affecting reproductive capabilities. Women who wish to have children in the future are influenced by their concern about possible issues with their fertility after a myomectomy. This affects their decision-making process regarding treatment and may even restrict the market's expansion.

Opportunity:

Rising demand for minimally invasive procedures

Patients increasingly favour minimally invasive techniques like laparoscopic or robotic-assisted myomectomy due to reduced recovery times, less scarring, and a quicker return to daily activities. This growing preference aligns with the desire for effective yet less invasive treatments, especially among women seeking fertility preservation. Furthermore, healthcare providers offering these advanced procedures can attract more patients seeking myomectomy, addressing the rising demand for minimally invasive options and potentially expanding the market.

Threat:

Non-surgical alternatives

Advanced non-surgical treatments like uterine artery embolisation (UAE) or focused ultrasound surgery (FUS) offer effective options for treating uterine fibroids without surgery. The availability and increasing success rates of these non-surgical treatments pose a challenge to the traditional myomectomy market, potentially reducing the demand for surgical procedures and impacting the market's growth by offering compelling alternatives for fibroid management without surgical interventions.

COVID-19 Impact

The COVID-19 epidemic severely impacted women's healthcare and the market for myomectomy procedures. It caused delays in diagnosis and treatment, as well as the postponement of non-urgent treatments in the medical field. Also, interruptions in the supply chain impacted the accessibility of medical supplies required for myomectomy operations. In addition, hospitals diverted funds for COVID-19 therapy, which affected the focus on non-urgent medical operations. Consequently, COVID-19 limited the growth of the myomectomy market.

The laparoscopic myomectomy segment is expected to be the largest during the forecast period

The laparoscopic myomectomy segment is estimated to hold the largest share. Laparoscopic myomectomy involves a minimally invasive surgical procedure to remove uterine fibroids. This technique utilizes small incisions through which specialized instruments and a laparoscope are inserted, providing a magnified view of the uterus. Moreover, it offers benefits like shorter hospital stays, faster recuperation, and reduced postoperative complications. With increasing patient preference for minimally invasive options and advancements in laparoscopic techniques, this segment continues to gain traction as a preferred method for treating uterine fibroids.

The hospitals & clinics segment is expected to have the highest CAGR during the forecast period

The hospitals & clinics segment is anticipated to have lucrative growth during the forecast period. Hospitals and clinics equipped with advanced medical infrastructure and skilled healthcare professionals cater to patients seeking various treatment options for uterine fibroids. They offer comprehensive diagnostic evaluations, surgical expertise, and postoperative care, addressing patient needs with diverse surgical approaches such as laparoscopic, robotic-assisted, or open myomectomy procedures. In addition, hospitals and clinics play a pivotal role in delivering specialised care, contributing significantly to the accessible and comprehensive management of uterine fibroids through myomectomy.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to the increasing number of women suffering from uterine disorders and the rising investment in the surgical device industry by key players in developing economies. China and Japan have played a significant role in the market expansion for myomectomy procedures. The supply of highly skilled medical personnel, including surgeons and gynaecologists, as well as the rising need for technologically sophisticated medical technologies, such as gene chips, for research purposes, are the main reasons for this growth.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to the rising prevalence of uterine fibroid and technological advancements in myomectomy procedures. According to the data updated by the United States Office on Women's Health in February 2021, it was estimated that about 20 percent to 80 percent of women developed fibroids by the time they reached age 50. Women in their 40s and early 50s are most likely to develop uterine fibroids. While not all fibroids cause symptoms, those who do frequently find living with their fibroids to be difficult. Thus, the high burden of uterine fibroids in the United States is expected to boost market growth.

Key players in the market:

Some of the key players in the Myomectomy Market include Medtronic, Conmed Corporation, Stryker Corporation, Insightec, Hologic, Inc, Cooper Surgical Inc, Intuitive Surgical, Braun Melsungen AG, Minerva Surgical Inc, Johnson And Johnson Services Inc., Karl Storz, Boston Scientific Corporation, General Electric Company, F. Hoffmann-La Roche Ltd, Richard Wolf Medical Instruments, Siemens, Bayer, AbbVie Inc. and Halt Medical, Inc.

Key Developments:

In November 2022, Olympus announced the market launch of the moresolution Power Morcellator, manufactured by TROKAMED GmbH and available in the United States through a distribution agreement with Olympus America, Inc. The moresolution Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens. Olympus's pneumoLiner and the moresolution Morcellator can provide select patients with a laparoscopic surgical option.

In April 2022, Ethicon, part of Johnson & Johnson MedTech, launched the ENSEAL X1 Straight Jaw Tissue Sealer. The ENSEAL X1 Straight Jaw is indicated for use in open and laparoscopic general, gynecological, and urologic procedures.

Products Covered:

  • Laparoscopic Power Morcellators
  • Laparoscopic Sealer
  • Harmonic Scalpel
  • Other Products

Types Covered:

  • Abdominal Myomectomy
  • Laparoscopic Myomectomy
  • Hysteroscopic Myomectomy
  • Robotic Myomectomy

End Users Covered:

  • Ambulatory Surgical Centers
  • Hospitals & Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Myomectomy Market, By Product

  • 5.1 Introduction
  • 5.2 Laparoscopic Power Morcellators
  • 5.3 Laparoscopic Sealer
  • 5.4 Harmonic Scalpel
  • 5.5 Other Products

6 Global Myomectomy Market, By Type

  • 6.1 Introduction
  • 6.2 Abdominal Myomectomy
  • 6.3 Laparoscopic Myomectomy
  • 6.4 Hysteroscopic Myomectomy
  • 6.5 Robotic Myomectomy

7 Global Myomectomy Market, By End User

  • 7.1 Introduction
  • 7.2 Ambulatory Surgical Centers
  • 7.3 Hospitals & Clinics
  • 7.4 Other End Users

8 Global Myomectomy Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Medtronic
  • 10.2 Conmed Corporation
  • 10.3 Stryker Corporation
  • 10.4 Insightec
  • 10.5 Hologic, Inc
  • 10.6 Cooper Surgical Inc
  • 10.7 Intuitive Surgical
  • 10.8 Braun Melsungen AG
  • 10.9 Minerva Surgical Inc
  • 10.10 Johnson And Johnson Services Inc.
  • 10.11 Karl Storz
  • 10.12 Boston Scientific Corporation
  • 10.13 General Electric Company
  • 10.14 F. Hoffmann-La Roche Ltd
  • 10.15 Richard Wolf Medical Instruments
  • 10.16 Siemens
  • 10.17 Bayer
  • 10.18 AbbVie Inc.
  • 10.19 Halt Medical, Inc.

List of Tables

  • Table 1 Global Myomectomy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Myomectomy Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
  • Table 4 Global Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
  • Table 5 Global Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
  • Table 6 Global Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 7 Global Myomectomy Market Outlook, By Type (2021-2030) ($MN)
  • Table 8 Global Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
  • Table 9 Global Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
  • Table 10 Global Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
  • Table 11 Global Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
  • Table 12 Global Myomectomy Market Outlook, By End User (2021-2030) ($MN)
  • Table 13 Global Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 14 Global Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 15 Global Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 16 North America Myomectomy Market Outlook, By Country (2021-2030) ($MN)
  • Table 17 North America Myomectomy Market Outlook, By Product (2021-2030) ($MN)
  • Table 18 North America Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
  • Table 19 North America Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
  • Table 20 North America Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
  • Table 21 North America Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 22 North America Myomectomy Market Outlook, By Type (2021-2030) ($MN)
  • Table 23 North America Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
  • Table 24 North America Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
  • Table 25 North America Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
  • Table 26 North America Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
  • Table 27 North America Myomectomy Market Outlook, By End User (2021-2030) ($MN)
  • Table 28 North America Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 29 North America Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 30 North America Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 31 Europe Myomectomy Market Outlook, By Country (2021-2030) ($MN)
  • Table 32 Europe Myomectomy Market Outlook, By Product (2021-2030) ($MN)
  • Table 33 Europe Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
  • Table 34 Europe Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
  • Table 35 Europe Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
  • Table 36 Europe Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 37 Europe Myomectomy Market Outlook, By Type (2021-2030) ($MN)
  • Table 38 Europe Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
  • Table 39 Europe Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
  • Table 40 Europe Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
  • Table 41 Europe Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
  • Table 42 Europe Myomectomy Market Outlook, By End User (2021-2030) ($MN)
  • Table 43 Europe Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 44 Europe Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 45 Europe Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 46 Asia Pacific Myomectomy Market Outlook, By Country (2021-2030) ($MN)
  • Table 47 Asia Pacific Myomectomy Market Outlook, By Product (2021-2030) ($MN)
  • Table 48 Asia Pacific Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
  • Table 49 Asia Pacific Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
  • Table 50 Asia Pacific Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
  • Table 51 Asia Pacific Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 52 Asia Pacific Myomectomy Market Outlook, By Type (2021-2030) ($MN)
  • Table 53 Asia Pacific Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
  • Table 54 Asia Pacific Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
  • Table 55 Asia Pacific Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
  • Table 56 Asia Pacific Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
  • Table 57 Asia Pacific Myomectomy Market Outlook, By End User (2021-2030) ($MN)
  • Table 58 Asia Pacific Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 59 Asia Pacific Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 60 Asia Pacific Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 61 South America Myomectomy Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 South America Myomectomy Market Outlook, By Product (2021-2030) ($MN)
  • Table 63 South America Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
  • Table 64 South America Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
  • Table 65 South America Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
  • Table 66 South America Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 67 South America Myomectomy Market Outlook, By Type (2021-2030) ($MN)
  • Table 68 South America Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
  • Table 69 South America Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
  • Table 70 South America Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
  • Table 71 South America Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
  • Table 72 South America Myomectomy Market Outlook, By End User (2021-2030) ($MN)
  • Table 73 South America Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 74 South America Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 75 South America Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 76 Middle East & Africa Myomectomy Market Outlook, By Country (2021-2030) ($MN)
  • Table 77 Middle East & Africa Myomectomy Market Outlook, By Product (2021-2030) ($MN)
  • Table 78 Middle East & Africa Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
  • Table 79 Middle East & Africa Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
  • Table 80 Middle East & Africa Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
  • Table 81 Middle East & Africa Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 82 Middle East & Africa Myomectomy Market Outlook, By Type (2021-2030) ($MN)
  • Table 83 Middle East & Africa Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
  • Table 84 Middle East & Africa Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
  • Table 85 Middle East & Africa Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
  • Table 86 Middle East & Africa Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
  • Table 87 Middle East & Africa Myomectomy Market Outlook, By End User (2021-2030) ($MN)
  • Table 88 Middle East & Africa Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 89 Middle East & Africa Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 90 Middle East & Africa Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)